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DAILY ADMINISTRATION OF PHYSOSTIGMINE DOES NOT 
AMELIORATE THE SPATIAL LEARNING IMPAIRMENTS INDUCED 
BY AF64A 
Trey Folkers, James Bedrosian, and Wayne Dornan*, 
Department of Psychology, IWU 
Alzheimer's Disease (AD) is a progressive degenerative disorder of the brain 
clinically manifested by cognitive deterioration. It usually begins in later life 
(> 65 years old), and results in death in about 3 to 10  years. Although 
originally thought to be a rare disease, AD has now reached startling 
proportions. It has been estimated that approximately 4 million Americans 
have AD, 19 million Americans say they have a family member with AD, and 
37 million know someone with AD. Although significant progress has been 
made toward understanding the etiology of AD, presently there is no known 
cause or treatment. Pathologically AD is characterized by a profound 
deficiency of the neurotransmitter, acetylcholine. As a result, an intense 
research effort revolves around palliative strategies using drugs that effect 
the cholinergic system. Presently, studies using "cholinergic enhancers" have 
produced the most encouraging results. In another study presented at this 
conference we found a dramatic impairment in spatial learning in animals 
treated with the cholinergic neurotoxin, AF64A. In this study we attempt to 
ameliorate the spatial learning deficits induced by AF64A by using the 
acetylcholinesterase inhibitor, physostigmine. Our preliminary results 
indicate that compared to controls, daily treatment of an acetylcholinesterase 
inhibitor does not improve performance on a spatial learning task in AF64A 
lesioned animals. The implications of these results for future treatment 
strategies regarding AD win be discussed at this conference. 
